Editas Medicine Unveils Updated Safety And Efficacy Results From The EdiTHAL Trial Of Reni-cel In 7 Patients With Transfusion-Dependent Beta Thalassemia At EHA
Portfolio Pulse from Benzinga Newsdesk
Editas Medicine has released updated safety and efficacy results from the EdiTHAL trial of reni-cel in 7 patients with transfusion-dependent beta thalassemia. All patients maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-infusion. Reni-cel was well-tolerated with a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant.
June 14, 2024 | 8:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Editas Medicine's EdiTHAL trial results show that all patients treated with reni-cel maintained hemoglobin levels above the transfusion threshold and are transfusion-free. The treatment was well-tolerated, indicating a positive safety profile.
The positive results from the EdiTHAL trial, showing that all patients are transfusion-free and the treatment is well-tolerated, are likely to boost investor confidence in Editas Medicine. This could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100